Temporal trends in pediatric cancer mortality: rare cancers lag behind more common cancers

Brian R Englum1, Shalini Sahoo1, Theodore W Laetsch2

  • 1University of Maryland School of Medicine, Baltimore, Maryland, USA.

PubMed

Insights

Survival rates for common pediatric cancers have significantly improved, but rare pediatric cancers still lag behind. Further research is crucial for these rare diseases to improve outcomes for all children with cancer.

Area of Science:

  • Pediatric Oncology
  • Cancer Epidemiology
  • Survival Analysis

Background:

  • Survival rates for common pediatric cancers have improved over time.
  • Little is known about survival trends for very rare pediatric cancers or how they compare to common ones.

Purpose of the Study:

  • To examine temporal trends in survival for pediatric cancers across different frequency groups (common, intermediate, rare).
  • To compare mortality improvements between common and rare pediatric cancers using a large population-based registry.

Main Methods:

  • Cohort study utilizing the Surveillance, Epidemiology, and End Results (SEER) registry (1975-2016).
  • Analysis included 50,222 patients (0-19 years at diagnosis), categorized by cancer frequency and decade of diagnosis.
  • Kaplan-Meier curves and adjusted Cox proportional hazards models were used to compare mortality trends.

Main Results:

  • Overall 5-year survival increased from 63% to 86% between the 1970s and 2010s.
  • Mortality hazard ratios decreased significantly more for common cancers (HR 0.27 in 2010s) compared to rare cancers (HR 0.60 in 2010s).
  • Rare cancers were more prevalent in older children and Black children.

Conclusions:

  • Pediatric cancer mortality has dramatically decreased since the 1970s, particularly for common cancers.
  • Rare pediatric cancers show slower survival improvements, underscoring the need for increased research and focus.
  • Targeted research efforts are essential to address the survival gap in rare pediatric cancers.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
155
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.0K
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
184
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
48.1K